Quellis Biosciences nabs $17 mln Series A

Boston-based Quellis Biosciences Inc., an emerging biopharmaceutical company focused on treating serious rare diseases, has raised $17 million in Series A financing.

Boston-based Quellis Biosciences Inc., an emerging biopharmaceutical company focused on treating serious rare diseases, has raised $17 million in Series A financing. Perceptive Xontogeny Venture Fund led the round.

Source: Press Release